Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Maturation of the Mfa1 Fimbriae in the Oral Pathogen Porphyromonas gingivalis.

Lee JY, Miller DP, Wu L, Casella CR, Hasegawa Y, Lamont RJ.

Front Cell Infect Microbiol. 2018 May 9;8:137. doi: 10.3389/fcimb.2018.00137. eCollection 2018.

2.

No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Mitchell TC, Casella CR.

Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17. Review.

3.

Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.

Kolb JP, Casella CR, SenGupta S, Chilton PM, Mitchell TC.

Sci Signal. 2014 Nov 11;7(351):ra108. doi: 10.1126/scisignal.2005442.

4.

Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A.

Casella CR, Mitchell TC.

PLoS One. 2013 Apr 26;8(4):e62622. doi: 10.1371/journal.pone.0062622. Print 2013.

5.

MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.

Cekic C, Casella CR, Sag D, Antignano F, Kolb J, Suttles J, Hughes MR, Krystal G, Mitchell TC.

J Immunol. 2011 Apr 1;186(7):3858-65. doi: 10.4049/jimmunol.1001034. Epub 2011 Feb 21.

6.

Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC.

J Biol Chem. 2009 Nov 13;284(46):31982-91. doi: 10.1074/jbc.M109.046383. Epub 2009 Sep 15.

7.

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Casella CR, Mitchell TC.

Cell Mol Life Sci. 2008 Oct;65(20):3231-40. doi: 10.1007/s00018-008-8228-6. Review.

8.

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC.

Science. 2007 Jun 15;316(5831):1628-32.

9.

Unrestrained glycogen synthase kinase-3 beta activity leads to activated T cell death and can be inhibited by natural adjuvant.

Sengupta S, Jayaraman P, Chilton PM, Casella CR, Mitchell TC.

J Immunol. 2007 May 15;178(10):6083-91.

10.

The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells.

Wang J, Shackelford JM, Casella CR, Shivers DK, Rapaport EL, Liu B, Yu XF, Finkel TH.

Virology. 2007 Mar 15;359(2):243-52. Epub 2006 Oct 23.

11.

Peptide-stimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment.

Thompson BS, Mata-Haro V, Casella CR, Mitchell TC.

Eur J Immunol. 2005 Nov;35(11):3196-208.

12.

A short domain within Bcl-3 is responsible for its lymphocyte survival activity.

Mitchell TC, Thompson BS, Trent JO, Casella CR.

Ann N Y Acad Sci. 2002 Dec;975:132-47.

PMID:
12538160
13.

Mapping of HIV-1 determinants of apoptosis in infected T cells.

Rapaport E, Casella CR, Ikl, Mustafa F, Isaak D, Finkel TH.

Virology. 1998 Dec 20;252(2):407-17.

14.
15.

Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication.

Casella CR, Raffini LJ, Panganiban AT.

Virology. 1997 Feb 17;228(2):294-306.

16.

Mechanisms of lymphocyte killing by HIV.

Casella CR, Finkel TH.

Curr Opin Hematol. 1997 Jan;4(1):24-31. Review.

PMID:
9050376
17.

Supplemental Content

Loading ...
Support Center